Increasing muscle mass improves vascular function in obese (DB/DB) Mice

Journal of the American Heart Association

Volumn 3, Issue 3, 2014, Pages

  Qiu, Shuiqing ^a   Mintz, James D ^a   Salet, Christina D ^a   Han, Weihong ^b   Giannis, Athanassios ^c   Chen, Feng ^a   Yu, Yanfang ^a   Su, Yunchao ^b   Fulton, David J ^a   Stepp, David W ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b AUGUSTA UNIVERSITY   (United States)

^c UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Muscle mass; Myostatin; NOX1; Oxidant stress; Tetrahydrobiopterin; Vasodilation

Indexed keywords

ENDOTHELIUM DERIVED HYPERPOLARIZING FACTOR; GKT 136901; GLUCOSE; INSULIN; MYOSTATIN; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; OXIDOREDUCTASE INHIBITOR; PROSTACYCLIN; SEPIAPTERIN; SUPEROXIDE DISMUTASE; TEMPOL; TETRAHYDROBIOPTERIN; UNCLASSIFIED DRUG; 2-(2-CHLOROPHENYL)-4-METHYL-5-(PYRIDIN-2-YLMETHYL)-1H-PYRAZOLO(4,3-C)PYRIDINE-3,6(2H,5H)-DIONE; AMINE OXIDE; AMINO ACID; CHROMIUM; GLUCOSE TOLERANCE TEST; NICOTINIC ACID DERIVATIVE; NITRIC OXIDE SYNTHASE; PTERIN DERIVATIVE; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SPIN LABELING;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL FUNCTION; CONTROLLED STUDY; ENDOTHELIUM; GENE DELETION; GENE EXPRESSION; GENE EXPRESSION REGULATION; GLUCOSE TOLERANCE; INSULIN RESISTANCE; LEAN BODY WEIGHT; MALE; MESENTERIC ARTERY; MOUSE; MUSCLE GROWTH; MUSCLE MASS; MYOSTATIN GENE; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEDENTARY LIFESTYLE; SKELETAL MUSCLE; VASCULAR DISEASE; VASODILATATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD VESSEL; DRUG EFFECTS; GENETICS; KNOCKOUT MOUSE; MOUSE MUTANT; MUSCLE STRENGTH; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; SPIN LABELING;

AMINO ACIDS; ANIMALS; BLOOD VESSELS; CHROMIUM; CYCLIC N-OXIDES; INSULIN RESISTANCE; MALE; MICE, KNOCKOUT; MICE, OBESE; MUSCLE STRENGTH; MUSCLE, SKELETAL; MYOSTATIN; NADPH OXIDASE; NG-NITROARGININE METHYL ESTER; NICOTINIC ACIDS; NITRIC OXIDE SYNTHASE; PTERINS; PYRAZOLES; PYRIDONES; REACTIVE OXYGEN SPECIES; REAL-TIME POLYMERASE CHAIN REACTION; SPIN LABELS; VASODILATION;

EID: 84939463111     PISSN: None     EISSN: 20479980     Source Type: Journal    
DOI: 10.1161/JAHA.114.000854     Document Type: Article

References (62)

1. Odegaard JI, Chawla A. Pleiotropic actions of insulin resistance and inflammation in metabolic homeostasis. Science. 2013;339:172-177.
2. Romeo GR, Lee J, Shoelson SE. Metabolic syndrome, insulin resistance, and roles of inflammation-mechanisms and therapeutic targets. Arterioscler Thromb Vasc Biol. 2012;32:1771-1776.
3. Odegaard JI, Chawla A. Mechanisms of macrophage activation in obesityinduced insulin resistance. Nat Clin Pract Endocrinol Metab. 2008;4:619-626.
4. Kolka CM, Bergman RN. The endothelium in diabetes: its role in insulin access and diabetic complications. Rev Endocr Metab Disord. 2013;14:13-19.
5. Virdis A, Neves MF, Duranti E, Bernini G, Taddei S. Microvascular endothelial dysfunction in obesity and hypertension. Curr Pharm Des. 2013;19:2382-2389.
6. Wang H, Luo W, Wang J, Guo C, Wang X, Wolffe SL, Bodary PF, Eitzman DT. Obesity-induced endothelial dysfunction is prevented by deficiency of Pselectin glycoprotein ligand-1. Diabetes. 2012;61:3219-3227.
7. Ali MI, Ketsawatsomkron P, Belin de Chantemele EJ, Mintz JD, Muta K, Salet C, Black SM, Tremblay ML, Fulton DJ, Marrero MB, Stepp DW. Deletion of protein tyrosine phosphatase 1b improves peripheral insulin resistance and vascular function in obese, leptin-resistant mice via reduced oxidant tone. Circ Res. 2009;105:1013-1022.
8. Stepp DW. Impact of obesity and insulin resistance on vasomotor tone: nitric oxide and beyond. Clin Exp Pharmacol Physiol. 2006;33:407-414.
9. Carter LG, Qi NR, de Cabo R, Pearson KJ. Maternal exercise improves insulin sensitivity in mature rat offspring. Med Sci Sports Exerc. 2013;45:832-840.
10. Izadpanah A, Barnard RJ, Almeda AJ, Baldwin GC, Bridges SA, Shellman ER, Burant CF, Roberts CK. A short-term diet and exercise intervention ameliorates inflammation and markers of metabolic health in overweight/obese children. Am J Physiol. 2012;303:E542-E550.
11. Hu G, Eriksson J, Barengo NC, Lakka TA, Valle TT, Nissinen A, Jousilahti P, Tuomilehto J. Occupational, commuting, and leisure-time physical activity in relation to total and cardiovascular mortality among Finnish subjects with type 2 diabetes. Circulation. 2004;110:666-673.
12. Park JH, Miyashita M, Kwon YC, Park HT, Kim EH, Park JK, Park KB, Yoon SR, Chung JW, Nakamura Y, Park SK. A 12-week after-school physical activity programme improves endothelial cell function in overweight and obese children: a randomised controlled study. BMC Pediatr. 2012;12:111.
13. Swift DL, Lavie CJ, Johannsen NM, Arena R, Earnest CP, O'Keefe JH, Milani RV, Blair SN, Church TS. Physical activity, cardiorespiratory fitness, and exercise training in primary and secondary coronary prevention. Circ J. 2013;77:281-292.
14. Forbes SC, Little JP, Candow DG. Exercise and nutritional interventions for improving aging muscle health. Endocrine. 2012;42:29-38.
15. Lee SJ. Extracellular regulation of myostatin: a molecular rheostat for muscle mass. Immunol Endocr Metab Agents Med Chem. 2010;10:183-194.
16. McPherron AC. Metabolic functions of myostatin and GDF11. Immunol Endocr Metab Agents Med Chem. 2010;10:217-231.
17. McPherron AC, Lawler AM, Lee SJ. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature. 1997;387:83-90.
18. Mosher DS, Quignon P, Bustamante CD, Sutter NB, Mellersh CS, Parker HG, Ostrander EA. A mutation in the myostatin gene increases muscle mass and enhances racing performance in heterozygote dogs. PLoS Genet. 2007;3:e79.
19. Schuelke M, Wagner KR, Stolz LE, Hubner C, Riebel T, Komen W, Braun T, Tobin JF, Lee SJ. Myostatin mutation associated with gross muscle hypertrophy in a child. N Engl J Med. 2004;350:2682-2688.
20. Hittel DS, Berggren JR, Shearer J, Boyle K, Houmard JA. Increased secretion and expression of myostatin in skeletal muscle from extremely obese women. Diabetes. 2009;58:30-38.
21. Bassil MS, Gougeon R. Muscle protein anabolism in type 2 diabetes. Curr Opin Clin Nutr Metab Care. 2013;16:83-88.
22. Lebrasseur NK. Building muscle, browning fat and preventing obesity by inhibiting myostatin. Diabetologia. 2012;55:13-17.
23. Britton KA, Massaro JM, Murabito JM, Kreger BE, Hoffmann U, Fox CS. Body fat distribution, incident cardiovascular disease, cancer, and all-cause mortality. J Am Coll Cardiol. 2013;62:921-925.
24. Manrique C, Demarco VG, Aroor AR, Mugerfeld I, Garro M, Habibi J, Hayden MR, Sowers JR. Obesity and insulin resistance induce early development of diastolic dysfunction in young female mice fed a Western diet. Endocrinology. 2013;154:3632-3642.
25. Karlsson HK, Ahlsen M, Zierath JR, Wallberg-Henriksson H, Koistinen HA. Insulin signaling and glucose transport in skeletal muscle from first-degree relatives of type 2 diabetic patients. Diabetes. 2006;55:1283-1288.
26. Meyer C, Dostou JM, Welle SL, Gerich JE. Role of human liver, kidney, and skeletal muscle in postprandial glucose homeostasis. Am J Physiol. 2002;282: E419-E427.
27. Shulman GI, Rothman DL, Jue T, Stein P, DeFronzo RA, Shulman RG. Quantitation of muscle glycogen synthesis in normal subjects and subjects with non-insulin-dependent diabetes by 13C nuclear magnetic resonance spectroscopy. N Engl J Med. 1990;322:223-228.
28. Guo T, Bond ND, Jou W, Gavrilova O, Portas J, McPherron AC. Myostatin inhibition prevents diabetes and hyperphagia in a mouse model of lipodystrophy. Diabetes. 2012;61:2414-2423.
29. Guo T, Jou W, Chanturiya T, Portas J, Gavrilova O, McPherron AC. Myostatin inhibition in muscle, but not adipose tissue, decreases fat mass and improves insulin sensitivity. PLoS One. 2009;4:e4937.
30. Wilkes JJ, Lloyd DJ, Gekakis N. Loss-of-function mutation in myostatin reduces tumor necrosis factor alpha production and protects liver against obesityinduced insulin resistance. Diabetes. 2009;58:1133-1143.
31. Tu P, Bhasin S, Hruz PW, Herbst KL, Castellani LW, Hua N, Hamilton JA, Guo W. Genetic disruption of myostatin reduces the development of proatherogenic dyslipidemia and atherogenic lesions in Ldlr null mice. Diabetes. 2009;58:1739-1748.
32. Stepp DW, Pollock DM, Frisbee JC. Low-flow vascular remodeling in the metabolic syndrome X. Am J Physiol Heart Circ Physiol. 2004;286:H964-H970.
33. Zhang R, Bai YG, Lin LJ, Bao JX, Zhang YY, Tang H, Cheng JH, Jia GL, Ren XL, Ma J. Blockade of AT1 receptor partially restores vasoreactivity, NOS expression, and superoxide levels in cerebral and carotid arteries of hindlimb unweighting rats. J Appl Physiol. 2009;106:251-258.
34. Zhang R, Ran HH, Ma J, Bai YG, Lin LJ. NAD(P)H oxidase inhibiting with apocynin improved vascular reactivity in tail-suspended hindlimb unweighting rat. J Physiol Biochem. 2012;68:99-105.
35. Ennen JP, Verma M, Asakura A. Vascular-targeted therapies for Duchenne muscular dystrophy. Skelet Muscle. 2013;3:9.
36. Ito K, Kimura S, Ozasa S, Matsukura M, Ikezawa M, Yoshioka K, Ueno H, Suzuki M, Araki K, Yamamura K, Miwa T, Dickson G, Thomas GD, Miike T. Smooth muscle-specific dystrophin expression improves aberrant vasoregulation in mdx mice. Hum Mol Genet. 2006;15:2266-2275.
37. Watts R, McAinch AJ, Dixon JB, O'Brien PE, Cameron-Smith D. Increased smad signaling and reduced mrf expression in skeletal muscle from obese subjects. Obesity. 2013;21:525-528.
38. Kim TN, Park MS, Yang SJ, Yoo HJ, Kang HJ, Song W, Seo JA, Kim SG, Kim NH, Baik SH, Choi DS, Choi KM. Body size phenotypes and low muscle mass: the Korean sarcopenic obesity study (KSOS). J Clin Endocrinol Metab. 2013;98:811-817.
39. Russell ST, Tisdale MJ. Mechanism of attenuation of skeletal muscle atrophy by zinc-alpha2-glycoprotein. Endocrinology. 2010;151:4696-4704.
40. Loffredo L, Martino F, Carnevale R, Pignatelli P, Catasca E, Perri L, Calabrese CM, Palumbo MM, Baratta F, Del Ben M, Angelico F, Violi F. Obesity and hypercholesterolemia are associated with NOX2 generated oxidative stress and arterial dysfunction. J Pediatr. 2012;161:1004-1009.
41. McPherron AC, Guo T, Wang Q, Portas J. Soluble activin receptor type IIB treatment does not cause fat loss in mice with diet-induced obesity. Diabetes Obes Metab. 2012;14:279-282.
42. DeFronzo RA, Tripathy D. Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. Diabetes Care. 2009;32:S157-S163.
43. Wang X, Hu Z, Hu J, Du J, Mitch WE. Insulin resistance accelerates muscle protein degradation: activation of the ubiquitin-proteasome pathway by defects in muscle cell signaling. Endocrinology. 2006;147:4160-4168.
44. Sloboda N, Feve B, Thornton SN, Nzietchueng R, Regnault V, Simon G, Labat C, Louis H, Max JP, Muscat A, Osborne-Pellegrin M, Lacolley P, Benetos A. Fatty acids impair endothelium-dependent vasorelaxation: a link between obesity and arterial stiffness in very old Zucker rats. J Gerontol A Biol Sci Med Sci. 2012;67:927-938.
45. Chinen I, Shimabukuro M, Yamakawa K, Higa N, Matsuzaki T, Noguchi K, Ueda S, Sakanashi M, Takasu N. Vascular lipotoxicity: endothelial dysfunction via fatty-acid-induced reactive oxygen species overproduction in obese Zucker diabetic fatty rats. Endocrinology. 2007;148:160-165.
46. Belin de Chantemele EJ, Vessieres E, Guihot AL, Toutain B, Maquignau M, Loufrani L, Henrion D. Type 2 diabetes severely impairs structural and functional adaptation of rat resistance arteries to chronic changes in blood flow. Cardiovasc Res. 2009;81:788-796.
47. Belin de Chantemele EJ, Vessieres E, Guihot AL, Toutain B, Loufrani L, Henrion D. Cyclooxygenase-2 preserves flow-mediated remodelling in old obese Zucker rat mesenteric arteries. Cardiovasc Res. 2010;86:516-525.
48. Romanko OP, Ali MI, Mintz JD, Stepp DW. Insulin resistance impairs endothelial function but not adrenergic reactivity or vascular structure in fructose-fed rats. Microcirculation. 2009;16:414-423.
49. Feletou M, Vanhoutte PM. Endothelium-derived hyperpolarizing factor: where are we now? Arterioscler Thromb Vasc Biol. 2006;26:1215-1225.
50. Gu Q, Wang B, Zhang XF, Ma YP, Liu JD, Wang XZ. Contribution of hydrogen sulfide and nitric oxide to exercise-induced attenuation of aortic remodeling and improvement of endothelial function in spontaneously hypertensive rats. Mol Cell Biochem. 2013;375:199-206.
51. Belin de Chantemele EJ, Ali MI, Mintz JD, Rainey WE, Tremblay ML, Fulton DJ, Stepp DW. Increasing peripheral insulin sensitivity by protein tyrosine phosphatase 1B deletion improves control of blood pressure in obesity. Hypertension. 2012;60:1273-1279.
52. Belin de Chantemele EJ, Muta K, Mintz J, Tremblay ML, Marrero MB, Fulton DJ, Stepp DW. Protein tyrosine phosphatase 1B, a major regulator of leptinmediated control of cardiovascular function. Circulation. 2009;120:753-763.
53. Belin de Chantemele EJ, Stepp DW. Influence of obesity and metabolic dysfunction on the endothelial control in the coronary circulation. J Mol Cell Cardiol. 2012;52:840-847.
54. Kulkarni AC, Kuppusamy P, Parinandi N. Oxygen, the lead actor in the pathophysiologic drama: enactment of the trinity of normoxia, hypoxia, and hyperoxia in disease and therapy. Antioxid Redox Signal. 2007;9:1717-1730.
55. Ray R, Murdoch CE, Wang M, Santos CX, Zhang M, Alom-Ruiz S, Anilkumar N, Ouattara A, Cave AC, Walker SJ, Grieve DJ, Charles RL, Eaton P, Brewer AC, Shah AM. Endothelial Nox4 NADPH oxidase enhances vasodilatation and reduces blood pressure in vivo. Arterioscler Thromb Vasc Biol. 2011;31:1368-1376.
56. Alp NJ, Channon KM. Regulation of endothelial nitric oxide synthase by tetrahydrobiopterin in vascular disease. Arterioscler Thromb Vasc Biol. 2004;24:413-420.
57. Forstermann U, Sessa WC. Nitric oxide synthases: regulation and function. Eur Heart J. 2012;33:829-837, 837a-837d.
58. Stroes E, Kastelein J, Cosentino F, Erkelens W, Wever R, Koomans H, Luscher T, Rabelink T. Tetrahydrobiopterin restores endothelial function in hypercholesterolemia. J Clin Invest. 1997;99:41-46.
59. Heitzer T, Brockhoff C, Mayer B, Warnholtz A, Mollnau H, Henne S, Meinertz T, Munzel T. Tetrahydrobiopterin improves endothelium-dependent vasodilation in chronic smokers: evidence for a dysfunctional nitric oxide synthase. Circ Res. 2000;86:E36-E41.
60. Alkaitis MS, Crabtree MJ. Recoupling the cardiac nitric oxide synthases: tetrahydrobiopterin synthesis and recycling. Curr Heart Fail Rep. 2012;9:200-210.
61. Crabtree MJ, Tatham AL, Hale AB, Alp NJ, Channon KM. Critical role for tetrahydrobiopterin recycling by dihydrofolate reductase in regulation of endothelial nitric-oxide synthase coupling: relative importance of the de novo biopterin synthesis versus salvage pathways. J Biol Chem. 2009;284:28128-28136.
62. Maier W, Cosentino F, Lutolf RB, Fleisch M, Seiler C, Hess OM, Meier B, Luscher TF. Tetrahydrobiopterin improves endothelial function in patients with coronary artery disease. J Cardiovasc Pharmacol. 2000;35:173-178.